JAPANESE ENCEPHALITIS VIRUS (JEV)
LEVELS: Highly unlikely: No controls necessary; Occupational exposure risk: Non-foodborne transmission pathway(s) that are strongly associated with occupational exposure and can lead to human infection; Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity; Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s); Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals; Prolonged disruption: Measureable negative effect on demand for more than 6 months when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); Available but uncertain efficacy: Commercial or autogenous vaccines exist in the US but protection may be inconsistent; Difficult and uncertain: Extremely difficult and with uncertain success rate, few global examples of success even at farm level
OVERVIEW
Japanese encephalitis virus (JEV) is an orthoflavivirus within the family Flaviviridae, first identified in Japan in 1933 following large summer epidemics of human encephalitis. JEV is the most important orthoflavivirus affecting swine and represents a major zoonotic pathogen causing an estimated 68,000 human encephalitis cases annually across southern, eastern, and southeastern Asia—with 20-30% case fatality rates and 30-50% of survivors developing long-term neuropsychological sequelae. Pigs serve as the primary amplifying host, developing high-titer viremia lasting 2-5 days that efficiently infects Culex mosquito vectors. JEV infection in pigs causes reproductive failure including abortion, stillbirths, mummified fetuses, and weak piglets with neurological signs, as well as temporary infertility in boars. The virus exists as five genotypes (GI-GV) with genotype Ib currently displacing older genotypes across temperate Asia. A significant 2022 outbreak in Australia demonstrated JEV's capacity to emerge in new regions, affecting over 80 commercial piggeries and causing 42 human cases with 7 deaths. Critically, direct pig-to-pig transmission via oronasal secretions has been demonstrated experimentally without mosquito involvement, and virus persists in tonsils for at least 25 days even in the presence of neutralizing antibodies.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
Humans become infected with JEV exclusively through the bite of infected Culex mosquitoes. No foodborne transmission from consumption of pork products has been documented despite JEV being endemic across Asia for nearly a century with extensive human exposure to pork from regions with high viral circulation. Humans are incidental dead-end hosts who do not develop viremia of sufficient magnitude to infect mosquito vectors. The virus targets neural and reproductive tissues in pigs rather than muscle tissue consumed as food. While virus can be detected in various pig tissues during acute infection, there is no epidemiological evidence linking pork consumption to human JEV cases.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Occupational exposure risk: Non-foodborne transmission pathway(s) that are strongly associated with occupational exposure and can lead to human infection
JEV poses significant occupational risk to people working with pigs in endemic areas. Amplification of JEV in pig populations precedes epidemic transmission to humans—pigs develop high-titer viremia (sufficient to infect mosquito vectors) and attract Culex mosquitoes that subsequently bite humans. Farm workers, veterinarians, and others with close contact to pigs in endemic regions are at elevated risk due to proximity to amplifying hosts and vector mosquitoes. Approximately 75% of human JE cases occur in children aged 0-14 years in rural communities where rice cultivation, pig production, and human habitation intersect. Most human infections (1 in 50 to 1 in 1000) are asymptomatic, but clinical cases carry 20-30% fatality and 30-50% long-term neurological sequelae. While direct pig-to-human transmission without mosquito involvement has not been documented, the experimental demonstration of pig-to-pig transmission via oronasal secretions raises theoretical concerns about direct exposure risks during handling of acutely infected animals.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity
JEV transmission fundamentally bypasses farm biosecurity because the virus is maintained and amplified through mosquito-bird-pig cycles that operate independently of pig movements or farm-level controls. Culex species mosquitoes—particularly C. tritaeniorhynchus throughout Asia and C. annulirostris in Australia—breed in rice paddies, wetlands, and standing water surrounding farms and cannot be excluded by standard biosecurity measures. Ardeid waterbirds (herons, egrets) serve as wildlife reservoir hosts, and migratory bird movements have been implicated in spreading JEV to new geographic areas. Wild boar and feral pigs also serve as reservoir/amplifier populations with approximately 30% seroprevalence documented in some regions. The 2022 Australian outbreak demonstrated that JEV can establish rapidly in new areas with receptive vectors and susceptible vertebrate hosts—retrospective evidence suggested silent circulation for months or years before detection. Additionally, direct pig-to-pig transmission via oronasal secretions has been experimentally confirmed, and virus persists in tonsils for at least 25 days post-infection even with neutralizing antibodies present, creating potential for within-farm spread independent of vectors.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s)
Clinical presentation of JEV in pigs—reproductive failure with stillbirths, mummified fetuses, and weak neonates—overlaps substantially with other causes including porcine parvovirus, PRRSV, classical swine fever, pseudorabies, and other pathogens, requiring laboratory confirmation for definitive diagnosis. In juvenile pigs, infection is usually inapparent or causes only nonspecific signs (pyrexia, inappetence, lethargy). Laboratory diagnosis is well-established: RT-PCR assays targeting conserved regions reliably detect JEV RNA in brain/CNS, placenta, lung, heart, tonsils, and body fluids from affected fetuses and neonates. Pan-genotype assays are recommended given ongoing genotype displacement patterns. Virus isolation in Vero, BHK, or C6/36 cells is achievable but requires 7-10 days. Serological testing (ELISA, HI, VN) is widely used but interpretation requires consideration of vaccination history, cross-reactions with related orthoflaviviruses, and maternal antibody persistence (waning at 3-4 months of age). The plaque-reduction neutralization test (PRNT) is the reference standard for specificity but requires BSL-3 facilities and specialized expertise.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals
JEV causes significant reproductive losses in endemic regions. Infection of pregnant sows at approximately 60-70 days gestation results in transplacental fetal infection causing abortion, stillbirths, mummified fetuses of varying sizes, and live but weak piglets that exhibit neurological signs (tremor, convulsion) and typically die shortly after birth. The 2022 Australian outbreak affected over 80 commercial piggeries across four states, causing substantial losses from mummified, aborted, and malformed piglets. In boars, JEV infection causes testicular edema and inflammation resulting in lowered motile sperm counts, abnormal spermatozoa, and temporary infertility—though complete recovery usually occurs. Juvenile and adult pigs generally survive infection without mortality, experiencing only self-resolving pyrexia and nonspecific clinical signs. In hyperendemic areas, annual losses occur predictably during mosquito seasons, representing a chronic production burden. The interplay between rice cultivation (mosquito breeding habitat), pig production, and human habitation in endemic Asian regions creates conditions for sustained transmission and ongoing reproductive losses.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Prolonged disruption: Measureable negative effect on demand for more than 6 months when disease occurs on one or more farms
JEV is an OIE/WOAH-listed disease due to its significant zoonotic impact and transboundary spread potential. Detection of JEV in a previously free country or region triggers immediate regulatory response and international notification. The 2022 Australian emergence resulted in public health emergency declarations, mandatory human vaccination programs for at-risk workers, and intensive surveillance across affected states. While JEV is endemic throughout much of Asia (limiting trade implications between endemic countries), emergence in JEV-free regions causes severe market disruption. Consumer and public health concerns about a virus causing fatal human encephalitis would generate significant pressure regardless of the actual food safety risk (which is negligible—JEV is mosquito-transmitted, not foodborne). Trade partners may impose restrictions pending demonstration of effective control. The combination of zoonotic severity, OIE listing, and demonstrated capacity for emergence in new regions places JEV among the highest market-impact pathogens for previously free countries.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
JEV is a viral pathogen (positive-sense RNA virus) that does not carry, acquire, or transmit antimicrobial resistance genes. The virus poses no AMR concerns regardless of disease epidemiology or management approaches. Orthoflaviviruses replicate in the cytoplasm using their own RNA-dependent RNA polymerase and do not interact with bacterial resistance mechanisms.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments exist for JEV infection in pigs. Disease management focuses on vaccination and mosquito control rather than therapeutic intervention. Antimicrobials are not indicated for uncomplicated JEV infection, which is viral. Secondary bacterial infections in affected animals might occasionally warrant antibiotic treatment, but JEV-associated disease does not drive significant antimicrobial use. The emphasis on prevention through vaccination and vector control means JEV management generates minimal selection pressure for antimicrobial resistance.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
There are no specific antiviral treatments for JEV infection in any species. Management of affected pigs is entirely supportive. Infected juvenile and adult pigs typically recover spontaneously with self-resolving pyrexia. However, reproductive losses (aborted, mummified, and stillborn fetuses) and neonatal deaths cannot be prevented once infection has occurred—treatment cannot reverse transplacental fetal damage. Weak piglets born with neurological signs following in utero infection typically succumb shortly after birth regardless of supportive care. Boar infertility following testicular involvement is usually temporary with spontaneous recovery. The absence of effective therapeutics places emphasis entirely on prevention through vaccination and vector control.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: Available but uncertain efficacy: Commercial or autogenous vaccines exist in the US but protection may be inconsistent
Several veterinary JEV vaccines exist, including inactivated and live-attenuated formulations based on genotype III strains (Nakayama, Beijing, AT222, and others). Live-attenuated vaccines or regimens including a LAV dose are typically more efficacious than inactivated vaccines alone. Annual vaccination of sows prior to peak seasonal JEV activity is practiced in endemic countries like South Korea and Taiwan to prevent reproductive losses. However, significant limitations exist: (1) High costs of immunizing large numbers of animals with rapid turnover; (2) Maternal antibodies interfere with piglet vaccination, persisting 3-4 months; (3) Cross-protection concerns—GIII-based vaccines show reduced efficacy against emerging GI and GIV strains, with field studies in Taiwan demonstrating GIII LAV was less effective at preventing stillbirth/abortion caused by circulating GI virus; (4) Limited duration of protection requiring annual revaccination. A novel chimeric BinJV/JEV-GIV vaccine candidate showed >94% protection against GIV challenge in pigs, addressing genotype matching concerns for the Australian outbreak strain. Widespread pig vaccination is not routinely practiced due to cost-benefit considerations in many endemic regions.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Difficult and uncertain: Extremely difficult and with uncertain success rate, few global examples of success even at farm level
JEV is not currently present in the United States, but if introduced, eradication would face severe challenges. The virus is maintained in transmission cycles involving Culex mosquitoes and wildlife hosts (ardeid birds, potentially bats) that cannot be eliminated through standard livestock disease control measures. Feral pig populations across the southern US could serve as amplifying hosts. Multiple competent Culex vector species are present throughout the continental US. The 2022 Australian experience demonstrated that JEV can circulate silently for extended periods before detection, potentially establishing in wildlife and vector populations before recognition. Eradication would require sustained, coordinated mosquito control across vast geographic areas—technically challenging and resource-intensive. Vaccination of domestic pigs could reduce amplification but would not eliminate wildlife-vector cycles. Historical precedent from endemic Asian countries shows JEV becomes permanently established once introduced into suitable ecological settings. Prevention of introduction through surveillance and biosecurity is far more feasible than post-introduction eradication.